Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | BCR | P11274 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5212172 | 0.88 | CNR2 (0.68) | CNR2KDM4ERAB9ACNR1CYP3A4 | |
| SCHEMBL5212332 | 0.79 | CNR2 (0.82) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5215525 | 0.78 | CNR2 (0.63) | CNR2RAB9ACNR1CYP3A4CYP2D6 | |
| SCHEMBL5213329 | 0.77 | CNR2 (0.62) | CNR2RAB9ACNR1ABL1BCR | |
| SCHEMBL12501226 | 0.77 | SMN1; SMN2 (0.58) | CNR2KDM4ECNR1CYP3A4CYP2D6 | |
| SCHEMBL12477077 | 0.75 | CNR2 (0.58) | CNR2KDM4ERAB9ACNR1CYP3A4 | |
| SCHEMBL31060708 | 0.75 | CNR2 (0.58) | CNR2KDM4ERAB9ACNR1CYP3A4 | |
| SCHEMBL14998689 | 0.74 | CNR2 (0.50) | CNR2KDM4ERAB9ACNR1CYP3A4 | |
| SCHEMBL3379094 | 0.74 | CNR2 (0.58) | CNR2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL3990475 | 0.74 | CNR2 (0.80) | CNR2KDM4ERAB9ACNR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | claimed |
| EP-1565442-B1 | PYRIDINE DERIVATIVES AS CB2 RECEPTOR MODULATORS | GLAXO GROUP LTD (GB) | 2007-11-14 | — | — | EP | disclosed |
| US-20060240048-A1 | Pyridine derivatives as cb2 receptor modulators | GLAXO GROUP LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060240048-A1 | Pyridine derivatives as cb2 receptor modulators | CNR2, CNR1, TRPV1 | CNR2 1/4885KDM4E 2124/4885RAB9A 1668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.